KORU MEDICAL SYSTEMS ANNOUNCES 2021 Q4

KORU MEDICAL SYSTEMS ANNOUNCES 2021 Q4 AND

FULL YEAR FINANCIAL RESULTS

- March 2, 2022 - Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical"

or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization

of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results

for the fourth quarter and full year ended December 31, 2021.

"We are very pleased to finish 2021 with a strong fourth quarter.

Driven by the efforts of our team, KORU Medical has seen momentum in all three areas of our business - domestic and international

core business and novel therapies," said Linda Tharby, KORU Medical's CEO. "During the fourth quarter, we hit several

key milestones, including three new 510(k) clearances, increased pump placements in our U.S. business, and four new agreements in our

novel therapies pipeline. In addition, we announced our new strategic plan, including milestones that will drive accelerated revenue growth,

margin improvement, and expansion of our total addressable market. We look forward to continued execution of our plan and driving long-term

growth and value for our patients, customers, employees, and shareholders."

2021 Fourth Quarter Financial Results

*This table represents Non-GAAP adjusted net revenues. See reconciliation

to GAAP table below.

Net revenues for the fourth quarter of 2021 were $6.5 million,

compared with $4.1 million in the prior-year period, a 60% increase. Adjusting for net inventory stocking of $1.0 million last

year, net revenues grew 27.6%, reflecting growth in all areas of the Company's business; domestic core growth driven by pumps

and consumables, international driven by consumables and increased novel therapies revenues from expansion of its pipeline.

Gross margin was 59.0% for the fourth quarter of 2021, an increase from

prior year of 56.6%. The majority of the increase was driven by a mid-year price increase.

Total operating expenses for the fourth quarter of 2021 were $5.9 million,

compared to $3.5 million for the same period in 2020. The increase in operating expenses

is due to strategic investments in commercialization, quality and regulatory, and research and development.

Net loss for the fourth quarter of 2021 was $1.1

million, or $(0.02) per diluted share, compared with a net loss of $0.8 million, or $(0.02) per diluted share for the same period in 2020.

Non-GAAP adjusted EBITDA for the fourth quarter of 2021 was $(0.6) million, compared with $(0.3) million in the fourth quarter of 2020.

On a non-GAAP basis, adjusted diluted earnings per share was $(0.02) per diluted share in both periods.

2021 Full Year Financial Results

Net revenues for 2021 were $23.5 million, 2.8%

lower compared with $24.2 million in the prior year. On an adjusted basis, net revenues were lower by 1.6%. The shortfall was driven by

lower year-over-year novel therapies revenues due to a large clinical trial order in 2020. Domestic core net revenues for 2021 were 0.8%

higher than last year mostly driven by price in the second half of the year and international core net revenues were up 14.5% compared

to the previous year, driven by growth in key customers.

Gross margin was 58.6% in 2021 compared to 61.8%

in 2020. The decrease was primarily driven by the delay in the transition to a secondary manufacturing source.

Total operating expenses increased 28.5%, or $4.6

million compared to last year. The increase was primarily driven by investments associated with building the Company's leadership

and extended team, commercialization and regulatory efforts, and research and development.

Net loss for the full year 2021 was $4.6 million, or $(0.10) per diluted

share, compared with a net loss of $1.2 million, or $(0.03) per diluted share for the same period in 2020. Non-GAAP adjusted EBITDA for

the full year 2021 was $(1.8) million, compared with $3.7 million for the same period in 2020. On a non-GAAP basis, adjusted diluted earnings

per share was $(0.07) for the full year 2021, compared with $0.02 diluted earnings per share for the same period in 2020.

The Company ended the year with $25.3 million of cash and believes it has

sufficient resources to execute its strategic plan over the next several years.

Assumptions and Outlook for Full Year Fiscal 2022

KORU Medical's outlook for fiscal year 2022 reflects numerous assumptions

that could affect its business, based on the information management has as of this date, which includes assumptions regarding the continued

recovery from the COVID-19 pandemic related to new SCIg patient starts, plasma supply, clinical trial activity, and supply chain impacts.

Management will discuss its outlook and several of its assumptions on its fourth fiscal quarter 2021 earnings call.

For fiscal year 2022, KORU Medical expects the subcutaneous immunoglobulin

(SCIg) market to recover and grow high single digits. Assuming this market growth holds, the Company expects revenue growth in the low

to mid double digits, or $26.0 to $27.0 million on a full year basis. Gross margin will be impacted by the supplier transition, which

the Company estimates will be completed in the third quarter of 2022 and expects to exit the year at a 60% run rate. The Company expects

operating expenses to increase to roughly $27.0 to $28.0 million for full year 2022 in support of the strategic plan, including investments

in building the team, research and development and commercialization efforts supporting new product introductions, novel therapies pipeline

expansion, and SCIg market penetration.

Conference Call and Webcast Details

The Company will host a live conference

call and webcast to discuss these results and provide a corporate update on Wednesday, March 2, 2022, at 4:30 PM ET.

To participate in the call, please

dial (877) 407-0784 (domestic) or (201) 689-8560 (international) and provide conference ID 13726808. The live webcast will be available

on the Events & Presentations page of the Investors section of KORU Medical's website.

This press release includes the non-GAAP

financial measures of "Adjusted Net Revenues," "Adjusted EBITDA" and "Adjusted Diluted EPS" that are

not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used

by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial

measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

They are limited in value because they exclude charges that have a material effect on KORU Medical's reported results and, therefore,

should not be relied upon as the sole financial measures to evaluate the Company's financial results. Non-GAAP financial measures

are meant to supplement, and to be viewed in conjunction with, GAAP financial results. Reconciliations of the Company's non-GAAP

measures are included at the end of this press release.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative

and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion

System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate

Tubing and HIgH-Flo Subcutaneous Safety Needle Sets . These devices are used for infusions administered

in the home and alternate care settings. For more information, please visit www.korumedical.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact

are forward-looking statements, including, but not limited to, expected financial outlook and operating performance for fiscal 2022, expected

market growth and availability of resources to execute the strategic plan. Forward-looking statements discuss the Company's current

expectations and projections relating to its financial position, results of operations, plans, objectives, future performance and business.

Forward-looking statements can be identified by words such as "outlook", "expect", "plan", "believe"

and "will". Actual results may differ materially from the results predicted and reported results should not be considered

as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results

predicted include, among others, uncertainties associated with the shift to increased healthcare delivery in the home, new patient diagnoses,

customer ordering patterns, COVID-19, innovation and competition, and those risks and uncertainties included under the captions "Risk

Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, which is on file with the SEC and is available

on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in

the attachments is as of March 2, 2022. Undue reliance should not be placed on the forward-looking statements in this press release, which

are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

REPRO MED SYSTEMS, INC.

STATEMENTS OF OPERATIONS